Clinical trial of donafenib combined with anti-PD-1 monoclonal antibody and transarterial chemoembolization in patients with unresectable hepatocellular carcinoma

GU Shanzhi; HUANG Manping; TAN Yulin; HU Hongtao; ZHU Xu; ZHENG Tongsen; ZHENG Zhendong; YUAN Mu

doi:10.3969/j.issn.1009-0460.2023.07.006

Home>Articles>Clinical trial of donafenib combined with anti-PD-1 monoclonal antibody and transarterial chemoembolization in patients with unresectable hepatocellular carcinoma

DOI: 10.3969/j.issn.1009-0460.2023.07.006

Clinical trial of donafenib combined with anti-PD-1 monoclonal antibody and transarterial chemoembolization in patients with unresectable hepatocellular carcinoma

GU Shanzhi

HUANG Manping

TAN Yulin

HU Hongtao

ZHU Xu

ZHENG Tongsen

ZHENG Zhendong

YUAN Mu

Keywords：Hepatocellular carcinomaDonafenibTransarterial chemoembolizationSafetyEfficacy

Publication Date：2023-07-28

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：6( 609-614 )

Chinese Clinical Oncology

ISTIC

ISSN：1009-0460

Year, Vol.(Issue)：2023,28(7)